This compound was identified in a cell-based promoter activity assay and was described to specifically abrogate survivin gene (BIRC5) expression, resulting in preclinical activity in several tumor models both in vitro and in vivo [22, 23]. The gene discussed is BIRC5; the disease is neoplasm.